Cutaneous S100‐negative, <scp>CD</scp>1a‐positive histiocytosis successfully treated with combination therapy of oral methotrexate and corticosteroid

Takahashi, Chiaki; Kaneta, Kazuhiro; Nomura, Wakana; Ohishi, Yasushi; Uehara, Jiro; Honma, Masaru; Ishida‐Yamamoto, Akemi; Sato, Hinako; Takagi, Akiyoshi; Iizuka, Hajime

doi:10.1111/1346-8138.12944

Cited by 2 publications

(1 citation statement)

References 9 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 In the current literature, there are only six reported cases of intermediate cell histiocytosis with negative S-100 (Table 1). [5][6][7][8][9][10] In the reported cases, only one of the six cases stated a potential triggera febrile illness that preceded two separate episodes of intermediate cell histiocytosis in a 3-year-old girl. 5 All six cases presented with cutaneous papules and/or plaques, with four being limited to the skin, one with corneal involvement and one with pulmonary involvement.…”

Section: Discussionmentioning

confidence: 99%

S100‐negative indeterminate cell histiocytosis: in an eight‐month‐old boy

Kong

Read²,

Pitney³

et al. 2020

Aust J Dermatology

View full text Add to dashboard Cite

myeloma, six months into this time period, after treatment with bortezomib by her oncologist. Despite paraprotein levels remaining stable for six months following chemotherapy, the rash did not resolve. Oral montelukast 10mg daily was added and, on review three months later, the patient had complete clinical resolution of the rash and its symptoms. Blood eosinophil levels normalised to 0.26x10^9/L. Her skin remained clear with ongoing montelukast after twelve months of follow-up. CONCLUSIONEosinophilic dermatosis of haematological malignancy tends to have a long, relapsing course with symptoms that negatively affect quality of life. Despite this, treatment options have been largely disappointing to date with most resulting only partial or no response. 3 Achieving complete resolution of the rash with montelukast in this patient therefore marks significant potential for a new effective treatment option for eosinophilic dermatosis of haematological malignancy.

show abstract

Section: Discussionmentioning

confidence: 99%

S100‐negative indeterminate cell histiocytosis: in an eight‐month‐old boy

Kong

Read²,

Pitney³

et al. 2020

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

A Case of Uncommon S100-Negative CD1a-Positive Histiocytosis in a 9-Year-Old Boy: Clinical Presentation, Histopathologic Features, and Successful Treatment Approach

Zhu,

Sun

2023

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Immunohistochemically, histiocytosis differentiating into Langerhans cells is typically characterized by the expression of CD1a, S100, and varying degrees of Langerin. However, CD1a-positive but S100-negative histiocytosis is extremely rare in clinical practice. We present a case of a 9-year-old boy with multiple erythematous to brown dome-shaped nodules. Histopathologic examination revealed dermal infiltrates of histiocytic cells, exhibiting a distinctive immunohistochemical profile of CD68+, S100−, CD1a+, and Langerin−. This exceptional case may contribute to our understanding of the etiology and differentiation processes of histiocytic proliferative disorders.

show abstract

Cutaneous S100‐negative, CD1a‐positive histiocytosis successfully treated with combination therapy of oral methotrexate and corticosteroid

Cited by 2 publications

References 9 publications

S100‐negative indeterminate cell histiocytosis: in an eight‐month‐old boy

S100‐negative indeterminate cell histiocytosis: in an eight‐month‐old boy

A Case of Uncommon S100-Negative CD1a-Positive Histiocytosis in a 9-Year-Old Boy: Clinical Presentation, Histopathologic Features, and Successful Treatment Approach

Contact Info

Product

Resources

About